Dainippon Sumitomo Seeks SFDA Approval for Cancer Drug
06:50 EDT 6 Sep 2012 | ChinaBio Today
Dainippon Sumitomo Pharma Co. of Osaka, Japan submitted an imported drug registration application to the SFDA in China for amrubicin HCI, an antibiotic, as a treatment for small cell cancer. The drug has been approved for use in Japan since 2002,..
Original Article: Dainippon Sumitomo Seeks SFDA Approval for Cancer Drug
More From BioPortfolio on "Dainippon Sumitomo Seeks SFDA Approval for Cancer Drug"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
